Applicant: Larry I. Benowitz
Serial No.: 09/872,347
Filed: 06/01/2001
Title: METHODS AND COMPOSITIONS FOR PRODUCING A NEUROSALUTARY EFFECT IN A SUBJECT

Examiner: L.I. Riuxiang
Group: 1646

In The Claims

Claim 1 (currently amended): A method comprising administering to a subject having a neuronal injury, a therapeutically effective amount of oncomodulin ~~a macrophage-derived factor~~, thereby producing ~~a neurosalutary~~ an effect or neuronal survival, regeneration, or axonal outgrowth in said subject.

Claim 2 (canceled)

Claim 3 (withdrawn)

Claim 4 (currently amended): The method of claim 1 , further comprising administering to said subject a non-hydrolyzable cAMP analogue ~~cAMP modulator~~.

Claim 5 (canceled)

Claim 6 (original): The method of claim 1, further comprising administering to said subject an axogenic factor.

Claim 7 (withdrawn)

Claim 8 (original): The method of claim 6, wherein the axogenic factor is inosine.

Claim 9 (canceled)

Claim 10 (canceled)

Claim 11 (canceled)

Claim 12 (currently amended): The method of claim 1, wherein the ~~neurosalutary~~ effect ~~is~~ produced in said subject ~~by modulating~~ is axonal outgrowth of central nervous system neurons.

Claim 13 (original): The method of claim 12, wherein the central nervous system neurons are retinal ganglion cells.

Claim 14 (currently amended): The method of claim 1, wherein the ~~macrophage-derived factor~~ oncomodulin is administered by introduction into a region of neuronal injury.

Claim 15 (currently amended): The method of claim 1, wherein the ~~macrophage-derived factor~~ oncomodulin is introduced into the cerebrospinal fluid of the subject.

Claim 16 (currently amended): The method of claim 1, wherein the ~~macrophage-derived factor~~ oncomodulin is introduced to the subject intrathecally.

Claim 17 (currently amended): The method of claim 1, wherein the ~~macrophage-derived factor~~ oncomodulin is introduced into a region selected from the group consisting of a cerebral ventricle, the lumbar area, and the cisterna magna of the subject.

Claim 18 (currently amended): The method of claim 1, wherein the ~~macrophage-derived factor~~ oncomodulin is administered to the subject in a pharmaceutically acceptable formulation.

Claim 19 (original): The method of claim 18, wherein the pharmaceutically acceptable formulation is a dispersion system.

Claim 20 (original): The method of claim 18, wherein the pharmaceutically acceptable formulation comprises a lipid-based formulation.

Claim 21 (original): The method of claim 20, wherein the pharmaceutically acceptable formulation comprises a liposome formulation.

Claim 22 (original): The method of claim 20, wherein the pharmaceutically acceptable formulation comprises a multivesicular liposome formulation.

Claim 23 (original): The method of claim 18, wherein the pharmaceutically acceptable formulation comprises a polymeric matrix.

Claim 24 (original): The method of claim 18, wherein the pharmaceutically acceptable formulation is contained within a minipump.

Claim 25 (currently amended): The method of claim 18, wherein the pharmaceutically acceptable formulation provides sustained delivery of the ~~macrophage-derived factor~~ oncomodulin for at least one week after the pharmaceutically acceptable formulation is administered to the subject.

A1

Claim 26 (original): The method of claim 18, wherein the pharmaceutically acceptable formulation provides sustained delivery of the ~~macrophage-derived factor~~ oncomodulin for at least one month after the pharmaceutically acceptable formulation is administered to the subject.

Claim 27 (original): The method of claim 1, wherein the subject is a mammal.

Claim 28 (original): The method of claim 27, wherein the mammal is a human.

Claim 29 (original): The method of claim 1, wherein said subject is suffering from a neurological disorder.

Claim 30 (original): The method of claim 29, wherein said neurological disorder is a spinal cord injury.

Claim 31 (original): The method of claim 30, wherein the spinal cord injury is characterized by monoplegia, diplegia, paraplegia, hemiplegia and quadriplegia

Claim 32 (withdrawn)

Claim 33 (withdrawn)

Claim 34 (withdrawn)

Claim 35 (canceled)

Claim 36 (canceled)

Claim 37 (canceled)

Claim 38 (withdrawn)

Q1 Claim 39 (withdrawn)

Claim 40 (withdrawn)

Claim 41 (withdrawn)

Claim 42 (withdrawn)

Claim 43 (withdrawn)

Claim 44 (original): A method comprising administering oncomodulin to a subject suffering from a neurological disorder, thereby treating said subject suffering from a neurological disorder.

Claim 45 (original): The method of claim 44, further comprising making a first assessment of a nervous system function prior to administering the oncomodulin to the subject and making a second assessment of the nervous system function after administering the oncomodulin to the subject.

Claim 46 (original): The method of claim 45, wherein the nervous system function is a sensory function, cholinergic innervation, or a vestibulomotor function